德視佳(01846.HK)與中國及德國頂尖醫科大學簽署三方相互合作協議
格隆匯7月27日丨德視佳(01846.HK)公吿,公司於2022年7月27日已與浙江大學醫學院附屬第二醫院眼科中心(浙江大學眼科醫院)及海德堡魯普雷希特-卡爾斯大學眼科診所的The David J. Apple International Laboratory for Ocular Pathology & International Vision Correction Research Centre(IVCRC) 訂立相互合作協議。
根據相互合作協議,訂約方同意在中華人民共和國("中國")及德國的眼科護理專業人士間建立更緊密的合作,促進集團在眼科領域的創新,提升集團外科醫生的技能,併為眼部護理的持續發展作出貢獻。
相互合作協議包括共同參與各自的科學及教育活動,例如研究項目及發表研究成果、宣傳活動及組辦會議,所有上述者均有助於提高眼科領域的突破。訂約方亦將設立青年醫生交流計劃,以進行科學研究、提高手術技能及分享不同方面的經驗。相互合作協議下符合參與資格的眼科醫生將有機會在中國及德國獲得三至六個月的獎學金。
根據相互合作協議,來自中國的參與者將能夠攻讀學位,並在集團的德國診所積累經驗。同時,來自德國的參與者將能夠參與研究項目並進行手術,以提升其在人工晶體手術、激光視力矯正及白內障併發症管理方面的經驗。
董事認為,監於中國對視力矯正服務的需求不斷增長,該計劃將有助於集團的外科醫生更深入瞭解中國市場並積累更多經驗,這將是集團全球擴張的重要環節。相互合作協議將會幫助集團識別任何未滿足的需求,併為中國患者提供最合適的專業知識及技術,同時在此重要市場培養新一代眼科醫生。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.